News & Updates

Generic antiobesity drugs viable after successful weight loss with GLP-1 RA

12 Dec 2024 by

Older-generation generic antiobesity medications (AOMs) for weight maintenance may be prescribed to patients who have achieved successful weight loss with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, suggests a study.

Generic antiobesity drugs viable after successful weight loss with GLP-1 RA

12 Dec 2024

Diet, exercise reduce serum lipids linked to insulin resistance

12 Dec 2024

Lifestyle interventions, including diet and exercise, can help lower serum sphingolipid species associated with insulin resistance, suggest the results of a recent study.

Diet, exercise reduce serum lipids linked to insulin resistance

12 Dec 2024

GLP1-RAs hold potential for asthma control

12 Dec 2024 by

Data presented at APSR 2024 demonstrate the ability of glucagon-like peptide 1 receptor agonists (GLP1-RAs) to benefit obese individuals with asthma.

GLP1-RAs hold potential for asthma control

12 Dec 2024

Pushing BP levels to lower targets better for cardioprotection in T2D

10 Dec 2024 by

Intensive systolic blood pressure (BP)-lowering treatment to reach target levels of less than 120 mm Hg is more beneficial than standard treatment in terms of reducing the risk of major cardiovascular events in Chinese patients with type 2 diabetes (T2D) and elevated BP, according to data from the BPROAD* trial.

Pushing BP levels to lower targets better for cardioprotection in T2D

10 Dec 2024

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

Cardiometabolic risk factors mediate link between body composition, bone mineral content

08 Dec 2024

The number of cardiometabolic risk (CMR) factors plays an important role in mediating the association between fat percentage and bone mineral content (BMC) percentage in children, suggests a study.

Cardiometabolic risk factors mediate link between body composition, bone mineral content

08 Dec 2024

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

05 Dec 2024 by

For individuals with type 2 diabetes mellitus (T2DM), the earlier the age at diagnosis, the higher the likelihood of subsequent coronary heart disease (CHD), stroke, cancer, and all-cause death, as shown in a study.

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

05 Dec 2024

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024 by

Testosterone replacement therapy (TRT) has the potential to be an effective adjunct treatment in the rehabilitation of critically ill patients with intensive care unit (ICU)-associated weakness (AW) and hospital-associated deconditioning (HAD), according to a Singapore study.

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

Use of tirzepatide results in better glycaemic control when compared with semaglutide, as shown by improved fasting glucose and glucose excursion control brought about by improvements in insulin secretion rate (ISR), insulin sensitivity, and glucagon suppression, according to a study.

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Generic antiobesity drugs viable after successful weight loss with GLP-1 RA

Generic antiobesity drugs viable after successful weight loss with GLP-1 RA

Diet, exercise reduce serum lipids linked to insulin resistance

Diet, exercise reduce serum lipids linked to insulin resistance

GLP1-RAs hold potential for asthma control

GLP1-RAs hold potential for asthma control

Pushing BP levels to lower targets better for cardioprotection in T2D

Pushing BP levels to lower targets better for cardioprotection in T2D

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Cardiometabolic risk factors mediate link between body composition, bone mineral content

Cardiometabolic risk factors mediate link between body composition, bone mineral content

Clinical considerations for patients at high risk for progression to severe COVID-19

Clinical considerations for patients at high risk for progression to severe COVID-19

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

Age at T2DM diagnosis a major factor for subsequent adverse outcomes

TRT shows promise as adjunct treatment in rehabilitating ICU patients

TRT shows promise as adjunct treatment in rehabilitating ICU patients

What drives the beneficial effects of tirzepatide on glycaemic control?

What drives the beneficial effects of tirzepatide on glycaemic control?